Advertisement

Topics

Companies Related to "Effect of Probiotic on Antibiotic-Associated Diarrhea" [Most Relevant Company Matches] RSS

10:11 EST 24th November 2017 | BioPortfolio

Here are the most relevant search results for "Effect of Probiotic on Antibiotic-Associated Diarrhea" found in our extensive corporate database of over 50,000 company records.

Showing "Effect Probiotic Antibiotic Associated Diarrhea" Companies 1–25 of 262

Wednesday 15th November 2017

Vibrent Health

Vibrent Health is powering the future of precision medicine. Through a software-as-a-service (SaaS) platform for individual and population health, Vibrent accelerates discoveries around the complex relationships of cause and effect in human health, advancing personalized health and precision medicine so people can lead healthier, longer lives. Vibrent part...


Wednesday 8th November 2017

Jaguar Health, Inc.

Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal ...

Monday 6th November 2017

EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinas...


Thursday 26th October 2017

Sancilio Pharmaceuticals Company, Inc.

Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies™ (ALT™) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and ...

Friday 29th September 2017

Peptilogics

Peptilogics is an early-stage biotechnology company developing a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Through rational design, this technology dramatically amplifies the antimicrobial activity of naturally-occu...

Wednesday 27th September 2017

ExeGi Pharma, LLC

ExeGi Pharma, LLC is a biotechnology company focused on the development and commercialization of live, biotherapeutic and probiotic medicines. ExeGi’s team leverages the growing advances in the field of microbiome science to deliver novel, clinically supported live biotherapeutic and probiotic treatments for a wide variety of unmet medical needs. For more ...

Wednesday 13th September 2017

ICONIC Protein

ICONIC Protein is one of the fastest-growing brands in the ready-to-drink protein beverage market with a passionate following of health-conscious consumers who have flocked to the brand’s healthy and great-tasting options. Made using dairy protein from grass-fed cows in New Zealand, ICONIC’s ready-to-drink beverage line is hormone, antibiotic and...

Tuesday 12th September 2017

VEP Healthcare, Inc.

VEP Healthcare began providing emergency medical management services in 1981. In the years since, the organization’s expertise has expanded into hospitalist services, intensive care, clinical decision units, telehealth, and surgicalist services. Today, the owners of VEP – the company’s physicians, advanced practice clinicians, and corporate ...

Thursday 10th August 2017

Symbiomix Therapeutics, LLC

Symbiomix (sim-bye-OH-mix) is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections that can have serious health consequences. The Company’s lead investigational drug Solosec™ (secnidazole) oral granules, a potent, next-generation 5-nitroimidazole antibiotic, is anticipated to be the first and ...

Tuesday 25th July 2017

ClinicalStudyDataRequest.com

ClinicalStudyDataRequest.com is the industry leader in global clinical trial data transparency. Its multi-sponsor Request System provides a secure process for researchers to request access to global clinical trial data through a publicly available website. An Independent Review Panel and process overseen by the Wellcome Trust review data requests received ...

VenatoRx Pharmaceuticals, Inc.

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel agents to address the threat of antibiotic bacteria resistance. Its lead clinical program combines VNRX-5133, a novel β-lactamase inhibitor, with an approved and marketed β-lactam antibiotic. This press release contains “forward-looking ...

Thursday 29th June 2017

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Wednesday 21st June 2017

Captozyme Inc.

Captozyme, Inc. is a biotechnology company developing enzymes and formulations to advance knowledge in the area of gut health and through our products advance the health and wellness of people. The company outsource manufacturing of Nephure to audited cGMP plants in Europe and the U.S., with plans to extend the product line around their IP-protected oxalat...

Thursday 20th April 2017

NAEJA-RGM Pharmaceuticals Inc.

NAEJA-RGM Pharmaceuticals Inc. is a global, early-stage drug discovery company with a promising new antibiotic project currently in preclinical development. NAEJA-RGM has other projects in various stages of development as well as a compound library developed over many years by Dr. Ronald G. Micetich’s drug discovery team. The headquarters and laborato...

Tuesday 11th April 2017

Appili Therapeutics Inc.

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential ...

Wednesday 8th March 2017

Farmhouse Culture

Since its founding in 2008, Farmhouse Culture® has quickly risen as a category leader in probiotic-rich foods and beverages. Fueled by growing consumer demand for gut-healthy foods, the company has expanded its product offerings beyond the Krauts it was founded on to include four varieties of fermented vegetables, Gut Shots™ probiotic drink line, and ...

Tuesday 21st February 2017

Discuva

Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens. The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates ...

Friday 10th February 2017

Pulse Biosciences, Inc.

Pulse Biosciences is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Stimulation, a proprietary cell signaling technology. Published pre-clinical studies have shown that a single, brief exposure of Nano-Pulse Stimulation to target tissue stimulates a cascade of events within cells and in the surrounding m...

Wednesday 23rd March 2016

Placon Therapeutics

Placon Therapeutics is a biotechnology company developing next-generation novel platinum medicines designed to improve the efficacy and side effect profile of today’s cytotoxic medicines that are widely used in cancer treatment. The company’s albumin-conjugating platinum drug candidates have long circulating half lives and preferentially accumula...

Wednesday 2nd March 2016

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Monday 8th February 2016

TOMTEC

Tomtec has succeeded since 1967 by working with its clients to help solve their liquid handling needs. From 1967 to 1981, the Company had essentially one employee, Tom Astle. From 1967 to 1971, the Company operated as Astec, Inc. In 1971 the Company's name was changed to Tomtec, and incorporated. Tom Astle has been the President and CEO since that time. In 1967, Tomtec developed the Autotiter. Thi...

Monday 18th January 2016

Telephus Medical LLC

Telephus Medical, located in San Diego, California, is developing a suite of monoclonal antibody products designed to neutralize key staphylococcal enzymes used to attach to host tissues, replicate and evade immune attack. These enzymes, are central components of the bacterial machinery staphylococci utilize to invade host tissues, evade the immune respons...

Wednesday 21st October 2015

Vyome Biosciences

Vyome Biosciences (www.vyome.in) is a clinical stage dermatology based biopharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant Acne, other opportunistic pathogens and antifungal agents. Vyome has put-together a team of scientific and management experts from India and USA to deliver compa...

Monday 5th October 2015

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Thursday 13th August 2015

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUT...


More From BioPortfolio on "Effect of Probiotic on Antibiotic-Associated Diarrhea"

Quick Search
Advertisement
 

Corporate Database Quicklinks